Timely access to new therapies is critical for patients, providing them with better treatment options and potentially life-saving solutions. The pharmaceutical industry faces pressure to develop new therapies rapidly and efficiently while maintaining data safety and quality.
The PROOF OF CONCEPT phase, particularly the "first-in-patient" clinical trials (Phase IB or IIA), is critical in the drug development process. It detects the initial efficacy signal of new therapies (compounds) in the targeted patient population. Data from these trials determine whether to continue or halt research of the respective new compound before significant investments in later phases of drug development.
The demand for advanced Phase I/II PROOF OF CONCEPT clinical trials requires specialized research personnel and facilities. However, traditional clinical trial sites often lack these resources, prompting pharmaceutical companies to involve multiple sites for trials, resulting in high costs and delays for protocols with low patient numbers (12-200).
At ARENSIA, we have addressed industry needs by establishing a proprietary network of research clinics in 8 countries over the past decade, spanning various therapeutic areas.
All ARENSIA Clinics are exclusively dedicated to expediting PROOF OF CONCEPT trials, ensuring the highest safety standards for patients and data quality.
Typical clinical trial sites encounter challenges like overcrowded schedules, insufficient staff, and prolonged contract negotiations. In contrast, ARENSIA Clinics achieve significant time reductions through unparalleled recruiting performance. By concentrating efforts on a select number of ARENSIA's research-dedicated clinics instead of a high number of clinical trial sites, we achieve a significant budget reduction for Phase IB/IIA PROOF-OF-CONCEPT trials.
Our 93% repeat business underscores that ARENSIA delivers a disruptive breakthrough in time and cost, fostering continuous growth and collaborations with leading pharmaceutical companies, biotechs, and global CROs.
In regards to patient enrollment, ARENSIA fulfilled their recruitment commitment and went on to enroll more patients than initially assigned. The ARENSIA Team demonstrated very high medical proficiency, trustworthiness and business sophistication.
We have very much appreciated the opportunity to work with ARENSIA and together further pioneer science. Not only did you help us enroll the study in record time, you have worked diligently to help us with a successful cohort lock. We look forward to continuing our partnership.
We are extremely happy and impressed with our partnership with ARENSIA. I already said a few times in our calls with the Sponsor and my team that I have never seen such a pace and successful collaboration in my 21 years in the industry.
With over a decade of specialized expertise in conducting sophisticated Phase IB and II trials, including pioneering first-in-class and best-in-class ...
READ MORESince its launch last year, ARENSIA’s Research Clinic in Phoenix, Arizona, has made remarkable progress, playing a pivotal role in Phase IB and ...
READ MOREIn Ukraine alone, rare diseases like IPF affect 10-15 people out of 100.000 population, typically diagnosed in individuals over 40. Without treatment,...
READ MOREWe love being in the lead! ARENSIA has once again achieved a significant milestone by enrolling the first patient globally, this time in a complex mul...
READ MOREToday, we honor the remarkable achievements, strength, and resilience of women worldwide. Let's stand united, empower each other, and continue bre...
READ MOREThe Health Authority (HA) of Moldova has introduced a 10-day fast-track review timeline for all phases (I-III) of clinical trials, with the regular re...
READ MOREFollowing a resonant success from San Francisco, we are thrilled to announce the next edition in the summit series: "RACE FOR PROOF OF CONCEPT...
READ MORE